Masimo (NSDQ:MASI) announced today that its Centroid wireless orientation, activity and respiration rate sensor received FDA clearance.
Centroid is a wearable sensor designed to monitor patient position in an effort to avoid preventable pressure ulcers, while also alerting clinicians to sudden movements, such as fall-like events. The device also detects chest movements to continuously provide respiration rate, offering data that could inform care decisions.
When paired with the Root patient monitoring and connectivity platform via Bluetooth, Centroid helps to track posture, orientation and activity. Data from these trackings can be displayed on Root in multiple ways, giving clinicians options in assessing protocols regarding tissue stress and patient needs.
Centroid, which can identify if a patient is lying down, standing, sitting upright, walking, or may have fallen, can also measure respiration accurately to within three respirations per minute (RPM) in the range of eight to 35 RPM, according to a news release.
The sensor for the device is designed for application on the chest with a gentle adhesive and a four-day battery that minimizes the need for frequent replacement.
“We are committed to using our expertise in signal processing and sensor design to develop new ways to provide the highest quality, most relevant data to clinicians in the most intuitive, useful formats, and Centroid, coupled with Root’s rich high-resolution display, is a great example of this,” Masimo founder & CEO Joe Kiani said in the release. “We hope that by helping to automate the process of tracking and making decisions about patient position, we can help clinicians reduce the frequency and severity of pressure ulcers, and ultimately improve patient outcomes.”
